DATOPOTAMAB DERUXTECAN
UNII GD2OWY1DTK

Substance Identification & Data

This profile provides standardized clinical and technical data for Datopotamab Deruxtecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) GD2OWY1DTK.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2238831-60-0 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

GD2OWY1DTK

CAS Registry Number

2238831-60-0

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

DATOPOTAMAB DERUXTECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

Molecular Formula

GD2OWY1DTK

The specific atomic composition represented as a molecular structure string.

NCI Thesaurus

C151967

National Cancer Institute reference terminology for clinical and research data.

INN ID

11218

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

LM-52

Identifier assigned by the United States Adopted Names Council.

Substance Type

Datopotamab Deruxtecan

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Datopotamab Deruxtecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Datopotamab Deruxtecan

Datopotamab Deruxtecan-DLNK

Common Names & Synonyms

ANTI-TROP2/DXD ANTIBODY-DRUG CONJUGATE DS-1062A

DATOPOTAMAB DERUXTECAN [USAN]

Datopotamab deruxtecan [WHO-DD]

Datopotamab deruxtecan dlnk [WHO-DD]

Immunoglobulin G1, anti-(human tumor-associated calcium signal transducer 2) (human-Mus musculus monoclonal MAAP-9001 γ1-chain), compd. with human-Mus musculus monoclonal MAAP-9001 κ-chain, dimer, thioether with N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]glycylglycyl-L-phenylalanyl-N-[[2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]amino]-2-oxoethoxy]methyl]glycinamide

datopotamab deruxtecan [INN]

immunoglobulin G1-kappa, anti-[Homo sapiens TACSTD2 (tumor-associated calcium signal transducer 2, membrane component chromosome 1 surface marker 1, M1S1, gastrointestinal tumor-associated antigen GA7331, pancreatic carcinoma marker protein GA733-1, epithelial glycoprotein-1, EGP-1, trophoblast antigen-2, cell surface glycoprotein Trop-2, TROP2)], humanized monoclonal antibody conjugated to deruxtecan, comprising a linker and a camptothecin derivative; gamma1 heavy chain humanized (1-451) [VH (Homo sapiens IGHV1-3*01(79.6%) -(IGHD) - IGHJ4*01 (93.3%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-121) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (218) (122-219), hinge 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (230-230'':233-233'')-bisdisulfide; produced in Chinese hamster ovary (CHO) cells, glycoform alfa, conjugated, on an average of 4 cysteinyl, to deruxtecan, comprising a linker and a camptothecin derivative